Advertisement
Canada markets closed
  • S&P/TSX

    22,308.93
    -66.90 (-0.30%)
     
  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     
  • DOW

    39,512.84
    +125.08 (+0.32%)
     
  • CAD/USD

    0.7317
    +0.0006 (+0.08%)
     
  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     
  • Bitcoin CAD

    83,340.97
    -2,764.30 (-3.21%)
     
  • CMC Crypto 200

    1,261.13
    -96.88 (-7.13%)
     
  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     
  • RUSSELL 2000

    2,059.78
    -13.85 (-0.67%)
     
  • 10-Yr Bond

    4.5040
    +0.0550 (+1.24%)
     
  • NASDAQ

    16,340.87
    -5.40 (-0.03%)
     
  • VOLATILITY

    12.55
    -0.14 (-1.10%)
     
  • FTSE

    8,433.76
    +52.41 (+0.63%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • CAD/EUR

    0.6789
    +0.0011 (+0.16%)
     

BioCryst: 4Q Earnings Snapshot

DURHAM, N.C. (AP) _ BioCryst Pharmaceuticals Inc. (BCRX) on Thursday reported a loss of $60.5 million in its fourth quarter.

The Durham, North Carolina-based company said it had a loss of 34 cents per share.

The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 25 cents per share.

The drugmaker posted revenue of $4 million in the period, which also missed Street forecasts. Four analysts surveyed by Zacks expected $14.7 million.

For the year, the company reported that its loss widened to $182.8 million, or $1.09 per share. Revenue was reported as $17.8 million.

ADVERTISEMENT

BioCryst shares have increased 59% since the beginning of the year. The stock has more than quadrupled in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BCRX at https://www.zacks.com/ap/BCRX